Results 71 to 80 of about 150,694 (118)

Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact? [PDF]

Cancer Chemother Pharmacol
Liersch P, Dierks S, Andag R, Liersch T, de Boer C, Kreutzer J, Hille A, Sülberg H, Leha A, Schanz J.   +9 more
europepmc   +1 more source

Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing. [PDF]

Cancer Chemother Pharmacol
Shamaei Zadeh A, Roberts D, Williams A, Pandey D, Villano JL.   +4 more
europepmc   +1 more source

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India. [PDF]

Pharmacogenomics
Raha R, Bhoyar RC, Biswal RP, Venkatakrishnan R, Rai P, Umashankar E, Kulkarni PM, Sivasubbu S, Scaria V, Jolly B.   +9 more
europepmc   +1 more source

DPD Ultra-Rapid Metabolizer Status and Efficacy of 5-Fluorouracil Treatment: A Real-World Study. [PDF]

Fundam Clin Pharmacol
Kallee G, Milano G, Duffaud F, Dahan L, Ciccolini J.   +4 more
europepmc   +1 more source

DPYD genotyping panels: Impact of population diversity. [PDF]

Clin Transl Sci
Suarez-Kurtz G.
europepmc   +1 more source

A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of <i>DPYD</i>: A Call to Revise European Pharmacogenetic Guidelines. [PDF]

Int J Mol Sci
Gil-Rodriguez A, Recarey-Rama S, Fernández Montes A, Rodríguez-Viyuela A, Barros F, Carracedo A, Maroñas O.   +6 more
europepmc   +1 more source

Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial. [PDF]

Br J Clin Pharmacol
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, Kukard C, Jayawardana M, Silva SSM, Alexander M, Tie J, Galettis P, Martin JH.   +12 more
europepmc   +1 more source

Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature. [PDF]

Cancer Chemother Pharmacol
Liguori C, Magi S, Mandolesi A, Agostini A, Svegliati-Baroni G, Benedetti Cacciaguerra A, Parisi A, Tiberi E, Vivarelli M, Giovagnoni A, Goteri G, Castaldo P, Berardi R, Giampieri R.   +13 more
europepmc   +1 more source

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity. [PDF]

Int J Cancer
Gambron M, Peruzzi E, Perfler S, Montico M, Cecchin R, De Mattia E, Spina M, Lisanti C, Corsetti S, Foltran L, Puglisi F, Roncato R, Cecchin E.   +12 more
europepmc   +1 more source

Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments. [PDF]

Eur J Hosp Pharm
Tejedor-Tejada E, Rubio Calvo D, García Andreo A.   +2 more
europepmc   +1 more source